MSB 2.55% $1.01 mesoblast limited

Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-23

  1. 144 Posts.
    lightbulb Created with Sketch. 44
    Long term data was not the reason that Mesoblast got a CRL response to their first submission, so why would Mesoblast wait to add this to the response to the resubmission?
    But the FDA wanted evidence of assays. Without that evidence it still isn't 100% that the survival is linked to the treatment. It could be just dumb luck and the two things may have no correlation.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.01
Change
0.025(2.55%)
Mkt cap ! $1.153B
Open High Low Value Volume
99.5¢ $1.02 99.0¢ $2.899M 2.888M

Buyers (Bids)

No. Vol. Price($)
77 243037 $1.00
 

Sellers (Offers)

Price($) Vol. No.
$1.01 29356 9
View Market Depth
Last trade - 13.01pm 28/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.